Research programme: antibody therapeutics - MorphoSys/Novartis

Drug Profile

Research programme: antibody therapeutics - MorphoSys/Novartis

Alternative Names: Anti-sclerostin antibody - Novartis/MorphoSys; Osteoporosis monoclonal antibody - Novartis/MorphSys

Latest Information Update: 12 Nov 2012

Price : $50

At a glance

  • Originator MorphoSys; Novartis
  • Class Monoclonal antibodies
  • Mechanism of Action SOST protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation; Osteoporosis

Most Recent Events

  • 24 Sep 2008 MorphoSys exercises its first option to participate in a therapeutic antibody development programme with Novartis
  • 23 Jun 2006 MorphoSys and Novartis have extended their collaboration agreement until May 2011
  • 08 Aug 2005 MorphoSys has achieved a performance-related milestone for developing fully human antibodies
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top